Qifa H. Ye

Hubei Key Laboratory Of Medical Technology On Transplantation
Wuhan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 242 publications

Dual-Oxidation Bacterial Cellulose Sponges with Rapid Shape Recovery for Crosslinker-Free Noncompressible Hemostasis and Tissue Regeneration.

Dual-Oxidation Bacterial Cellulose Sponges with Rapid Shape Recovery for Crosslinker-Free Noncompressible Hemostasis and Tissue Regeneration.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: June 27, 2026

Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury.

Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury.

Journal: ACS nano

Published: April 30, 2026

Biocompatible Quaternized Chitosan-Whey Protein Nanofibrous Porous Microspheres for Multi-Functional Synergistic Regulation of the Gut-Liver Axis in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Biocompatible Quaternized Chitosan-Whey Protein Nanofibrous Porous Microspheres for Multi-Functional Synergistic Regulation of the Gut-Liver Axis in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: April 16, 2026

Mild hypothermic pretreatment alleviates hepatic ischemia-reperfusion injury by reducing CIRP-dependent NETosis-related hepatocyte pyroptosis.

Mild hypothermic pretreatment alleviates hepatic ischemia-reperfusion injury by reducing CIRP-dependent NETosis-related hepatocyte pyroptosis.

Journal: Cellular signalling

Published: March 26, 2026

Retraction Note: FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.

Retraction Note: FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.

Journal: Journal of translational medicine

Published: February 20, 2026

Hypothermic machine perfusion attenuates DCD liver ischemia reperfusion injury via the YAP1/P53-mediated micromitophagy pathway.

Hypothermic machine perfusion attenuates DCD liver ischemia reperfusion injury via the YAP1/P53-mediated micromitophagy pathway.

Journal: Free radical biology & medicine

Published: December 18, 2025

Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.

Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.

Journal: Frontiers in immunology

Published: December 17, 2025

Ubc9-mediated SUMOylation of Ninj1 alleviates inflammatory responses in hepatic ischaemia/reperfusion injury.

Ubc9-mediated SUMOylation of Ninj1 alleviates inflammatory responses in hepatic ischaemia/reperfusion injury.

Journal: Clinical and translational medicine

Published: December 12, 2025

Imidazolium salt chitosan based on bacterial capture: Antimicrobial mechanisms, biosafety, and methicillin-resistant Staphylococcus aureus-infected wound healing.

Imidazolium salt chitosan based on bacterial capture: Antimicrobial mechanisms, biosafety, and methicillin-resistant Staphylococcus aureus-infected wound healing.

Journal: Carbohydrate polymers

Published: December 10, 2025

Coagulation-Independent Hemostasis Through Architecturally Programmed Chitosan Aerogels with Dual-Crosslinked Networks.

Coagulation-Independent Hemostasis Through Architecturally Programmed Chitosan Aerogels with Dual-Crosslinked Networks.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: November 20, 2025

HepAssis2® bioartificial liver system in treating acute-on-chronic liver failure patients: Findings from a phase 1 randomised, open-label clinical trial.

HepAssis2® bioartificial liver system in treating acute-on-chronic liver failure patients: Findings from a phase 1 randomised, open-label clinical trial.

Journal: Clinical and translational medicine

Published: November 17, 2025

HSPH1 and DNAJB1 as potential key regulators in hepatic ischemia-reperfusion injury.

HSPH1 and DNAJB1 as potential key regulators in hepatic ischemia-reperfusion injury.

Journal: Molecular immunology

Published: October 20, 2025

Showing 1-12 of 242

Last Updated: 09/26/2026